Elraglusib combined with platinum chemotherapy showed potential benefits in select patients with recurrent, metastatic ...

Welcome to the final edition of The Targeted Pulse of 2025, your weekly wrap-up of the top developments in oncology. This ...

FDA approves CBI-1214 for colorectal cancer, enabling fast-tracked clinical trials and highlighting innovative T-cell engager ...

Salvage Efficacy: Most significantly, for the 8 patients who showed no response to initial TCE monotherapy, the addition of ...

BGB-B2033, a bispecific antibody, targets 4-1BB and GPC3, showing potential in advanced hepatocellular carcinoma (HCC) ...

Liquid biopsy using ctDNA refines risk stratification for patients with residual cancer burden post-neoadjuvant therapy, ...

Findings from a study on the utility of ultrasensitive circulating tumor DNA (ctDNA) as a predictive biomarker for patients ...

Michael Wang, MD, professor at The University of Texas MD Anderson Cancer Center, details the rationale for a long-term ...

Laura Huppert, MD, highlights patient-reported outcomes from the phase 3 ASCENT-04 trial which compared first-line treatment ...

Laura Huppert, MD, discusses the results of the phase 3 ASCENT-03 trial, which compared the antibody-drug conjugate ...

Pelareorep (Reolysin), an intravenously delivered oncolytic virus immunotherapy, has demonstrated positive second-line ...

A combination of the antibody-drug conjugate enfortumab vedotin (Padcev) and the PD-1 inhibitor pembrolizumab (Keytruda) ...